What if diseases could be treated with a patient’s own cells, precisely and on demand? Biotech entrepreneur Nabiha Saklayen explains how we could harness advances in biology, machine learning and lasers to create personalized stem cell banks — and develop medicine uniquely designed for each of our bodies.

We started this competition with 20 impressive startups. After three days of fierce pitching in the virtual yet incredibly competitive Startup Battlefield arena, we have a winner: Cellino.

Cellino, a company developing a platform to automate stem cell production, presented today at TechCrunch Disrupt 2021 to detail how its system, which combines A.I. technology, machine learning, hardware, software — and yes, lasers! — could eventually democratize access to cell therapies. It aims to bring down costs associated with the manufacturing of human cells, […]

Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Are autologous iPSC-derived cell therapies ready to hit prime time? A conversation between Alex Morgan, Partner at Khosla Ventures, and a panel of distinguished experts in autologous iPSC cell therapies will address the breakthroughs in the space. What new advancements in autologous cell therapies are already available to make sure patients can best benefit given […]

Nabiha Saklayen is co-founder and chief executive of US start-up Cellino Biotech, which uses biophysics technologies to advance personalized regenerative medicine. She talks to Julianna Photopoulos about the importance of multidisciplinarity for tackling real-world problems.

Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced that its CEO Dr. Nabiha Saklayen has been awarded the first Tory Burch Fellowship at the International Genomics Institute (IGI).

Fast Company announces new partnership with Tory Burch Foundation and Jennifer Doudna and the Innovative Genomics Institute, featuring their inaugural one-year fellowship program to support entrepreneur and scientist Nabiha Saklayen, PhD, Co-Founder & CEO of Cellino, a company working on personalized cell therapies.

Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for patients.

The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as a starting material for autologous, or patient‐specific, stem cell–based therapies. Since the first publications describing the generation of iPSCs from human tissue in 2007, a Phase I/IIa clinical trial testing an autologous iPSC‐derived cell therapy has been initiated in […]

During the holidays, Alex Morgan, Partner at Khosla Ventures, sat down with Nabiha Saklayen, CEO and co-founder of Cellino, to learn more about her and the company.  Cellino has a unique technique technology for AI-guided laser editing of stem cells for personalized therapies. The company’s goal is to make autologous stem cell manufacturing scalable for the first time.  […]

CEO Nabiha Saklayen founded Cellino in 2017 while still in her mid-20s (she’s since gone on to be named to Forbes’ 30 Under 30 list and MIT Tech Review’s 35 Innovators Under 35 list), and told Endpoints News in a statement that the technology has the potential to eliminate “a major bottleneck” in the stem cell […]

Cambridge, Mass.-based Cellino has raised $16 million in venture capital to scale up a technology that could be vital as stem-cell research expands. Its system is designed to automate the now labor-intensive process of generating induced-pluripotent stem cells that are derived from patients’ own cells.

Top-tier investor syndicate co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC. The financing will be used to advance its AI-guided laser platform to automate and scale autologous cell-and tissue-based therapies.

A Forbes 30 Under 30 alum from 2019, Cellino Biotech is making waves— and tissues. The Cambridge, Massachusetts-based company, backed by the Engine at MIT, uses new technology to create regenerative tissues out of pluripotent stem cells. In other words, they’re creating lab-grown tissues and organs that can one day restore vision loss and treat other diseases.